-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 16, 2022, Seagen and Sanofi announced an exclusive collaboration agreement to design, develop and commercialize antibody drug conjugates (ADCs) against up to three cancer targets
ADCs consist of three parts: monoclonal antibodies targeting specific antigens on the tumor surface, cytotoxic drugs that can kill tumor cells, and linkers that connect the cytotoxic drugs to the antibody
Under the terms of the partnership, Seagen and Sanofi will jointly fund global development activities and share equally in any future profits
References:
[1] Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates.
(Original abridged)